Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy to Dish Out Its New Anti-Diabetic Drug, Balaglitazone, by 2011 (India)

This article was originally published in PharmAsia News

Executive Summary

Dr. Reddy Laboratories recently announced the success of its new diabetes drug, Balaglitazone, in late-stage clinical trials. If the drug continues to perform well, Dr. Reddy anticipates it will be available worldwide by 2011. The company is also moving to begin investing $100 million a year in research and development to find new treatments for cancer, diabetes, cardiovascular problems, inflammation and bacterial infections. Dr. Reddy already has eight experimental formulas in its pipeline designed to fight diabetes, inflammation and obesity. Dr. Reddy is developing Balaglitazone with Denmark's Rheoscience. Dr. Reddy will retain rights for 60 percent of the diabetes market, including the United States. (Click here for more

You may also be interested in...



Dr. Reddy's Makes Headway With Phase III PPAR Compound; Will It Be The First Innovative Indian Product To Reach The Market?

MUMBAI - Hope was rekindled for India's Dr. Reddy's Labs to put its own experimental drug in the market after the Hyderabad-headquartered company announced that its lead type 2 diabetes compound balaglitazone succeeded in meeting the primary endpoint in Phase III trials

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel